GlassScriptPhysician profile
Brenda L Holmes
NPI 1164553459
$3,773.40
in general payments reported to CMS, 2019-2025
25 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $1,004 · 2023: $1,119 · 2024: $621 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $932.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $562.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $453.80 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $203.29 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $201.97 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $162.58 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $158.76 | 2022-2023 | |
| Lilly USA, LLC | $140.94 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Axsome Therapeutics, INC. | $116.67 | 2025 | Sunosi |
| Abbott Laboratories | $115.72 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $115.62 | 2023-2025 | |
| Esperion Therapeutics, INC. | $111.17 | 2021 | |
| Merck Sharp & Dohme LLC | $79.55 | 2022-2023 | Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $59.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.66 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $50.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.66 | 2021-2022 | |
| Exact Sciences Corporation | $47.03 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $42.13 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $25.91 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.15 | 2024 | Xifaxan |
| Dynavax Technologies Corporation | $19.83 | 2022 | |
| Halozyme INC | $16.66 | 2023 | |
| Medtronic, INC. | $14.56 | 2025 | Midas Rex |
| Amneal Pharmaceuticals LLC | $14.26 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.